Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7443904 + Glofitamab in r/r B-cell NHL
NCT05219513Phase 1Terminated
- Sponsor
- Roche
- Start
- Feb 2022
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of RO7443904 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Roche. Primary endpoints: Dose-limiting toxicities at 21 days and Adverse Events. Started Feb 2022; status: terminated.
02
Drugs
RO7443904
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05219513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219513.